Drug intelligence / Profile preview

Yishenjuanbi Prescription

Development stage: Unknown
Lead developer: Zhejiang Provincial People's Hospital
Administration: Oral

Overview

Yishenjuanbi (also known as Yishen Juanbi Prescription or Decoction) is a Traditional Chinese Medicine (TCM) formula developed for the treatment of ankylosing spondylitis (AS). The name reflects its therapeutic principle: "Yishen" (tonifying the kidney) and "Juanbi" (eliminating arthralgia/rheumatism). It is primarily studied by Zhejiang Provincial People's Hospital for its ability to reduce systemic inflammation, improve clinical symptoms, and regulate bone metabolism. In clinical research, it is often evaluated in randomized, double-blind, placebo-controlled trials to establish its efficacy and safety profile as a therapeutic option for AS patients.

Other names: Yishen Juanbi PrescriptionYishen Juanbi DecoctionYSJBDYishenjuanbi-tang

Beyond the preview

Go deeper on Yishenjuanbi Prescription.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yishenjuanbi Prescription.

Explore the full profile